Please login to the form below

Not currently logged in
Email:
Password:

GSK’s 2011 sales dip but Witty confident for 2012

Company expects sales to return to growth this year

GlaxoSmithKline's (GSK) sales fell 3 per cent to £27.4bn last year as the company was hit by increased generic competition and the loss of revenues from its key diabetes drug.

Avandia faced prescribing restrictions US and was withdrawn from the market entirely in Europe after it was linked to an increased risk of cardiovascular events.

But sales for 2012 are expected to return to growth and GSK said it expects to complete development programmes for another six late-stage products and indications.

These include asthma treatment Relovair, chronic obstructive pulmonary disease drug LABA/LAMA and albiglutide for type 2 diabetes, although in November it did disappoint in a phase III trial when compared to Novo Nordisk's Victoza (liraglutide).

The remaining three products are skin cancer therapy BRAF, HIV/AIDS treatment dolutegravir and malaria vaccine Mosquirix.

CEO Andrew Witty acknowledged development of its type 1 diabetes candidate otelixizumab had been halted during 2011, but said “overall the balance of 'progression versus failure' was positive for GSK”.

Witty said GSK was “working hard to try and reposition the group for exactly this period that we knew would come” with the company looking to make the most of patent losses for rival companies and increased price pressures.

He said: “We feel like we are moving into a new era for the company and we now need to focus on absolute disciplined execution to make sure that we take advantage of all of the opportunities that we've worked so hard to try and create for ourselves.”

GSK also saw gains due to restructuring efforts, which have reportedly seen annual savings of £2.2bn for the company since being implemented in 2007.

8th February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics